Aclaris Therapeutics, INC

Aclaris Therapeutics has amended its at-the-market sales agreement, allowing for continued offering of common stock through sales agents.

Aclaris Therapeutics announced its second quarter 2026 financial results, highlighting positive Phase 1a trial data for ATI-052 and reaffirming timelines for key clinical readouts, with a cash runway extending through 2028.

Aclaris Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of executive compensation.

Aclaris Therapeutics reported Q1 2026 financial results, highlighting positive Phase 1a data for ATI-052 and confirming a cash runway through 2028.

Aclaris Therapeutics announces positive Phase 1a results for ATI-052, supporting potential for extended dosing, and selects lichen planus as the lead indication for ATI-2138.

Aclaris Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting positive interim Phase 1a results for ATI-052 and progress across its immuno-inflammatory disease pipeline.

Aclaris Therapeutics reports increased R&D expenses and net losses in Q2 2026, driven by clinical trial advancements, while securing $57.9 million in financing.

Aclaris Therapeutics reported increased revenue and a wider net loss in its Q1 2026 filing, with significant investment in R&D for its immuno-inflammatory disease pipeline.

Aclaris Therapeutics, Inc. reported a significantly wider net loss in the third quarter and first nine months of 2025, driven by increased research and development expenses, despite positive clinical progress for its pipeline candidates.

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, reported an increased net loss and decreased revenue for Q2 2025, driven by higher R&D expenses for key drug candidates and lower licensing income, while maintaining sufficient liquidity for over 12 months.

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its Q1 2025 financial results, highlighting a net loss of $15.1 million and progress in its immuno-inflammatory disease pipeline.

Aclaris Therapeutics announced its third quarter 2024 financial results, alongside updates on its strategic review and clinical development programs.

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $64.9 million for 2025, while advancing its immuno-inflammatory disease pipeline and seeking third-party partnerships.

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announces its 2024 financial results and highlights its focus on developing novel treatments for immuno-inflammatory diseases.

Aclaris Therapeutics' 10-K filing details the company's capital stock, voting rights, anti-takeover provisions, and regulatory compliance, providing a comprehensive overview of its corporate structure and operational framework.

Roland Wilhelm Kolbeck, Chief Scientific Officer of Aclaris Therapeutics, Inc., reported multiple transactions in common stock on August 1, 2026.

Aclaris Therapeutics Director Anand Mehra reported transactions involving common stock, including the acquisition of stock options and restricted stock units.

Aclaris Therapeutics Director Andrew Schiff reported transactions involving common stock, stock options, and restricted stock units.

William D. Humphries, a Director at Aclaris Therapeutics, Inc., reported transactions involving the acquisition and disposition of company stock and equity awards.

Christopher P. Molineaux, a Director at Aclaris Therapeutics, Inc., reported transactions involving the acquisition of common stock and restricted stock units.

Vincent Milano, a Director at Aclaris Therapeutics, Inc., reported transactions involving common stock, stock options, and restricted stock units.

Aclaris Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, detailing proposals for director elections, executive compensation, and auditor ratification.

Aclaris Therapeutics is holding its 2025 Annual Meeting on June 5, 2025, seeking stockholder votes on director elections, executive compensation, an increase in authorized common stock, approval of an equity incentive plan, and ratification of the company's independent auditor.

Aclaris Therapeutics is asking stockholders to vote on key proposals including increasing authorized common stock and approving a new equity incentive plan at the upcoming annual meeting.

Aclaris Therapeutics, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 6, 2024, with proxy materials now available for review and voting.

Aclaris Therapeutics' upcoming annual meeting on June 6, 2024, will address director elections, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the company's independent auditor.

RA Capital Management, along with affiliated entities and individuals, has reported a beneficial ownership of 9.1% of Aclaris Therapeutics' common stock as of June 30, 2026.

Vivo Opportunity Fund Holdings and related entities report a combined beneficial ownership of approximately 4.8% in Aclaris Therapeutics, Inc.

BML Investment Partners, L.P. has filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Aclaris Therapeutics, Inc.

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have filed a joint Schedule 13G, indicating beneficial ownership of 6.3% of Aclaris Therapeutics, Inc. common stock.

The Vanguard Group has reported a 0% beneficial ownership in Aclaris Therapeutics Inc. following an internal realignment.

Deep Track Capital and its affiliates have reported a 7.0% beneficial ownership stake in Aclaris Therapeutics, Inc., totaling 9,345,000 shares.